Abu Dhabi puts biological age to the test

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

A two-year partnership with Ultrahuman aims to connect clinical biomarkers and wearable data, bringing aging assessment into public health.

Ask a longevity clinic how old you really are and the answer tends to arrive as a single, faintly flattering number. Ask a government how old its population really is, and whether that number can tell it who will fall ill next, and the arithmetic becomes considerably harder. Abu Dhabi intends to try.

The emirate’s Public Health Centre (ADPHC) has signed a two-year Memorandum of Understanding with Ultrahuman to develop and validate a Biological Health Age model, folding clinical biomarkers together with wearable data on cardiovascular health, sleep, metabolism and recovery. On paper, the goal is earlier intervention – catching the slow drift toward chronic disease while there is still time to correct course. In practice, the project tests something the longevity field has largely taken on trust: that biological age can be measured reliably enough, and at sufficient scale, to change what a health system does next.

For longevity biotech, a good deal rides on the answer. Any therapy that claims to slow aging will one day need a way to prove it, and a measure robust enough to shape public health policy might eventually earn a regulator’s attention. Might. The route from a wearable’s overnight readings to a trial endpoint runs through some stubborn science, and Abu Dhabi has just signed up to walk it.

Longevity.Technology: A biological age sold to a customer and one commissioned by a health ministry are quite different instruments. The first has every commercial reason to be encouraging; the second is only worth having if it is right, singling out the people who will go on to develop heart disease or diabetes, and doing so earlier than the blood-pressure cuff and the cholesterol panel already manage. That is a far more demanding brief, and a welcome one for a field in which clocks have multiplied rather faster than evidence that they change anything. Combining clinical biomarkers with continuous wearable data should yield a fuller account of an individual’s health. It is less clear that this amounts to a measure of aging; a composite built largely from established cardiometabolic risk factors may simply restate what those factors already predict, with a new label and a more persuasive interface. The more durable value may lie in what the program leaves behind – years of measurements tied to clinical outcomes in the same population, the kind of resource that cohorts such as UK Biobank took decades to accumulate and that geroscience still has too little of. An MoU commits nobody to results. It does suggest, however, that governments are beginning to treat healthspan as something to be measured as well as promised.

A new layer on an old stack

Under the agreement, the two parties will carry out joint research and clinical validation, stitching clinical results and wearable readings together into a single estimate of how quickly someone is aging. The data stays put. Both have committed to keeping it inside the emirate, under clinical oversight and governance rules written into the MoU – a clause that, in an era of increasingly assertive data sovereignty, carries rather more weight than its position in a press release might suggest.

For ADPHC, the model adds a new layer to an existing stack. Abu Dhabi has invested heavily in genomics, with the Emirati Genome Programme sequencing citizens since 2021, and in digital health infrastructure that already follows patients through the system. Add a continuous stream of physiological data and researchers could, in principle, watch the same people’s sleep and cardiovascular health shift over years, then see what became of them. Few clinical trials last long enough to manage anything of the kind.

His Excellency Dr Rashed Obaid Alsuwaidi, Director General of ADPHC (far right) and Mohit Kumar, Founder and Chief Executive Officer of Ultrahuman Healthcare (far left) at the signing of the Memorandum of Understanding.

His Excellency Dr Rashed Obaid Alsuwaidi, Director General of ADPHC, said that public health is evolving from a model which is centered primarily on disease management to one that focuses increasingly on prediction, prevention and early intervention. “Understanding how populations age and identifying the factors that influence healthy longevity are essential components of that transition,” he said. “This collaboration will help strengthen our ability to generate evidence, develop new public health tools and translate data into practical insights that support healthier communities across Abu Dhabi.”

Which clock, whose time?

Biological age has an awkward secret, which is that there is no single version of it. Horvath’s original epigenetic clock, GrimAge, PhenoAge and DunedinPACE all read DNA methylation, yet each was trained on something different – chronological age, mortality risk, the measured pace of physiological decline – and they can return quite different verdicts on the same person. Other models bypass the epigenome entirely and work from blood chemistry, grip strength or clinical risk scores. Comparing their outputs is a little like checking a sundial against a station clock.

Ultrahuman’s model adds another ingredient: physiology logged night after night, filling the long gaps between blood draws. The signal is noisy, though. A bout of flu, a week of broken sleep or an ambitious new training plan can all shift the readings without the underlying biology aging a day. Validation will have to show that the model can tell the difference, and that it predicts disease better than the risk scores clinicians already use.

This is where biotech’s interest sharpens. Tracking someone’s health status is one task; demonstrating that a gerotherapeutic has slowed their aging is another, and it is the second that the industry needs. A dependable longitudinal measure could help find and monitor trial participants. Persuading the FDA to accept one as a surrogate endpoint, in a regulatory system that does not yet recognize aging as an indication, would take evidence of an altogether heavier order. Abu Dhabi’s data may add to that case. It will not close it.

The value of scale

Abu Dhabi’s public health system offers a chance to study these measurements away from the tidy conditions of a research protocol. Habits, health and environment vary there as they do in life, and interpretation gets correspondingly harder.

Mohit Kumar, Founder and CEO of Ultrahuman Healthcare, said: “This collaboration represents an important opportunity to combine continuous health monitoring with one of the world’s most advanced health ecosystems. Abu Dhabi has created an exceptional environment for developing and validating population-scale health innovations, and we are proud to contribute to this important work alongside ADPHC.”

Much remains unsettled – who will take part, how long they will be followed and will a model built in the Gulf hold up anywhere else. Better prediction does not guarantee better outcomes either, nor lower costs; all that depends on whether anyone actually behaves differently once the risk is known.

Beyond the numbers

As governments work out how to meet aging populations, preventive medicine is increasingly expected to produce evidence of its own value. Abu Dhabi has two years to start supplying some.


Wondering which longevity biotechs could benefit from better biological age measurement? Ask DLT to “show me companies developing biomarkers of aging for clinical trials” or to “identify longevity biotechs using biological age clocks to assess therapeutic efficacy” – explore the platform HERE.

Photograph courtesy of Ultrahuman Healthcare

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Novartis exits a BioArctic deal worth up to $802m

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE